|Videos|July 29, 2019
Tyrosine Kinase Inhibitors Used Alone or in Combination to Treat RCC
Advertisement
Episodes in this series
Transcript:
Advertisement
Related to this article
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Praful Ravi, MB, BChir, MRCP, discusses the LASER futility readout, PSMA heterogeneity in clear cell RCC, and next steps for radiopharmaceuticals.
Daniel Heng, MD, MPH, FRCPC, discusses data from LITESPARK-011, second-line RCC sequencing, and managing belzutifan-associated anemia and hypoxia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
4
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
5